Could less immunotherapy be better? new trial tests Every-6-Week dosing for tough breast cancer

NCT ID NCT07401537

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether giving immunotherapy every 6 weeks instead of every 3 weeks works as well for advanced triple-negative breast cancer. The goal is to keep the cancer under control while reducing side effects and improving quality of life. About 416 participants whose cancer is stable or improving after initial treatment will be randomly assigned to one of the two schedules.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
PD-1 inhibitor (immunotherapy drug)
What this could lead to
If successful, this could show that less frequent immunotherapy is just as effective, with fewer side effects and lower costs for patients with advanced triple-negative breast cancer.
What could go wrong
This is a Phase 2 trial, so results are preliminary. The extended schedule might be less effective or still cause significant side effects. It only applies to patients whose cancer is stable or improving after initial treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Breast Tumor Center, Sun Yat-sen Memorial Hospital

    RECRUITING

    Guangzhou, Guangdong, 510000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.